Clinical Trial Update: Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and efficacy of Bendamustine, Gemcitabine, Rituximab, and Nivolumab (BeGeRN) in relapsed/refractory diffuse large B-cell lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Gemcitabine (Gemcitabine)
• Rituximab (rituximab)
• nivolumab (nivolumab)

Snippet

Sponsor: St. Petersburg State Pavlov Medical University | Conditions: Diffuse Large B Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED